Modality
Degrader
MOA
Cl18.2
Target
CD123
Pathway
Fibrosis
PSPALLNSCLC
Development Pipeline
Preclinical
Oct 2023
→ Feb 2029
PreclinicalCurrent
NCT03755186
1,979 pts·ALL
2023-10→2029-02·Not yet recruiting
1,979 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-02-172.9y awayInterim· ALL
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
Preclinical
Not yet…
Catalysts
Interim
2029-02-17 · 2.9y away
ALL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03755186 | Preclinical | ALL | Not yet recr... | 1979 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 | |
| Zorizumab | Beam | Approved | CD123 | |
| ELV-1411 | Enliven | NDA/BLA | HER2 | |
| Gelitapinarof | MacroGenics | Approved | CDK2 |